2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1918 Safety and efficacy of relmacabtagene autoleucel (relma-cel) in adult patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL):Results from two open-label, single-arm study

Xiangrui Meng, MD, Lanfang Li2, Zheng Song3, Zhengzi Qian4, Lihua Qiu5, Xianlin Duan6, Songyun Zhao7, Huilai Zhang, PhD8
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
6 JW Therapeutics (Shanghai) Co. Ltd, Shanghai, China
7 JW Therapeutics (Shanghai) Co. Ltd, Shanghai, China
8 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Background: Relma-cel, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, is an approved treatment for relapsed or refractory (R/R) large B-Cell lymphoma (LBCL). To reduce manufacturing costs and enhance supply chain stability, an in-house lentiviral vector manufacturing process was established. Two post-approval bridging studies (a prospective investigator initiated trial [IIT] and an investigational New Drug [IND] application trial)  were conducted to evaluate the safety and efficacy of relma-cel manufactured using the domestically produced lentiviral vector (JWLV011).

Aims: To assess the efficacy, safety and pharmacokinetic (PK)/ pharmcodynamic (PD) profiles of relma-cel manufactured with JWLV011 in adult patients with R/R LBCL.

Methods: Both studies employed identical inclusion and exclusion criteria and enrolled adults (≥18 years) with histologically confirmed R/R LBCL who had relapsed or progressed after ≥2 prior systemic therapies, including an anthracycline-containing regimen and anti-CD20 monoclonal antibody, or following autologous stem cell transplantation. Patients underwent lymphodepleting chemotherapy consisting of cyclophosphamide (250 mg/m2/day × 3 days) and fludarabine (25 mg/m2/day × 3 days), followed by a single infusion of relma-cel at a dose of 100 × 106 CAR+ T cells. The primary endpoint was investigator-assessed objective response rate (ORR) at 3 months post-infusion.

Results: As of the data cutoff dates (IIT: Oct 16, 2025; IND: July 13, 2026), 26 patients underwent leukapheresis, and 22 received relma-cel infusion. The median age was 58 years (range: 35–76; 31.8% ≥65 years), and 63.6% were male. At baseline, 50.0% had an International Prognostic Index (IPI) score 3-5, 9.1% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1, and 9.1% had Bulky Disease lesion≥7.5cm in diameter. A total of 45.4% of patients had received at least three prior lines of systemic therapy. Overall, 50% had relapsed disease, and 68.2% were refractory to their most recent therapy; 50% received bridging therapy.

In the modified intent to treatment (mITT) population (n=22), the investigator-assessed overall response rate (ORR) at 3 months was 63.6%, with a complete response rate (CRR) of 36.4%, meeting the primary endpoint. The best investigator-assessed ORR was 72.7%, with a best CRR of 50.0%. After follow up 12 months, the progression-free survival (PFS) rate for all patients was 40.4%; among those achieving a complete response (CR), the PFS rate was 71.6%. Median overall survival (OS) and duration of response (DOR) were not reached, the 12-month OS rate for all patients was 77.3% (Figure 1).

In the Pharmacokinetic Analysis Set (PKS) population, based on qPCR assessment, peak cellular concentrations in subjects occurred between Days 8 and 15, with a median Tmax of 11 days. The median Cmax was 38,430.50 copies/μg, and the median AUC1-29 was 273,609.15 day·copies/μg. These key pharmacokinetic parameters were consistent with those from previous clinical studies using existing overseas vectors in patients with relapsed/refractory large B-cell lymphoma.

Relma-cel manufactured with JWLV011 demonstrated a manageable safety profile with no treatment-related deaths, or study discontinuations due to adverse events. All patients experienced treatment-related adverse events (TEAE), 18.2% developed serious TEAE. Cytokine release syndrome occurred in 90.9% of patients, most (95%) has grade 1-2. No patient developed neurological toxicities.

Conclusions: Relma-cel manufactured using the domestically produced lentiviral vector demonstrated favorable efficacy and a manageable safety profile in adult patients with R/R LBCL. These findings support the feasibility of in-house lentiviral vector manufacturing without compromising clinical performance.

Xiangrui Meng, MD: No relevant conflicts of interest to declare.